Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug -; dupilumab -; that showed rapid and sustained improvements in patients in a pivotal Phase 3 clinical trial, researchers report in the New England Journal of Medicine.
Dupilumab shows promising results in Phase 3 trial for COPD with type 2 inflammation
- Thread starter Educator
- Start date